A NEW preclinical study has revealed a potentially game-changing approach to treating pancreatic cancer, one of the most lethal and treatment-resistant malignancies. Researchers at the Spanish National Cancer Research Centre report that a combination of three targeted drugs was able to completely eliminate pancreatic tumours and prevent them from returning in multiple laboratory models. The findings offer fresh hope for overcoming the resistance that has long limited the effectiveness of pancreatic cancer therapies.
Pancreatic ductal adenocarcinoma (PDAC), which accounts for the vast majority of pancreatic cancer cases, is known for its aggressive nature and poor survival outcomes. Many patients are diagnosed at advanced stages, and even when tumours respond to therapy, resistance often develops rapidly. As a result, long-term disease control has remained extremely difficult to achieve.
Instead of focusing on a single molecular target, the research team adopted a broader strategy by blocking three interconnected cancer-driving pathways at the same time. Their goal was to prevent tumour cells from switching to alternative survival routes when one pathway is shut down, a common mechanism behind drug resistance.
Coordinated three-pathway attack
The study centres on KRAS, a gene that is mutated in most PDAC cases and acts as a master switch for tumour growth. Rather than targeting KRAS alone, the scientists inhibited several critical signalling routes linked to it such as RAF1, which functions downstream of KRAS and supports tumour proliferation; EGFR family receptors, which sit upstream and help activate cancer-promoting pathways; and STAT3, a parallel survival pathway that enables tumour cells to escape treatment
According to the authors, simultaneously disabling these three ‘nodes’ led to complete and lasting regression of pancreatic tumours driven by KRAS and TP53 mutations. By attacking the cancer from multiple directions, the tumour cells were left without a way to adapt or recover.
Three drugs, one powerful combination
The experimental therapy combines RMC-6236 (daraxonrasib), a KRAS-targeting compound; Afatinib, which blocks EGFR family receptors; and SD36, a selective degrader of STAT3.
READ ALSO: Positive results emerge on cancer treatment amid rising deaths in Nigerian hospitals
The drugs were tested in orthotopic mouse models, where tumour cells were implanted directly into the pancreas to closely mimic human disease. In these models, the triple therapy did more than shrink tumours – it eradicated them. Even more striking, the cancer did not return for over 200 days after treatment stopped, with no evidence of tumour resistance.
Consistent effects across diverse models
To confirm the strength of their results, the researchers tested the combination in several additional systems. These included genetically engineered mouse models of pancreatic cancer and patient-derived tumour xenografts using human cancer tissue grown in mice.
In all cases, the therapy caused significant tumour regression and sustained growth suppression. The animals tolerated the treatment well, suggesting the combination could have a favourable safety profile for future clinical development, Drug Target Review said.
Potential solution to treatment resistance
Resistance has been one of the most stubborn barriers in pancreatic cancer care. Tumours often evolve quickly, rendering single-target drugs ineffective. The new findings suggest that a multi-target approach may finally offer a way to overcome this challenge.
As the researchers noted, durable control of PDAC requires coordinated inhibition of KRAS downstream, upstream, and parallel survival pathways. By blocking all three at once, the tumour loses its ability to bypass treatment, reducing the likelihood of relapse.
What this means for patients
While the therapy has not yet been tested in humans, the study lays important groundwork for future clinical trials. The authors say their data should guide the development of new treatment strategies that use combination targeting to improve outcomes for patients with PDAC.
If similar effects are seen in clinical settings, this approach could mark a major step forward, not only shrinking tumours, but keeping them from coming back. For a cancer that has long resisted conventional treatments, the prospect of durable remission represents a powerful shift in what may soon be possible.
